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Abstract
Background: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency
and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis,
treatment patterns of European patients with IPF were investigated to understand antifibrotic prescribing and
identify unmet needs in IPF treatment practice.
Methods: Between February and March 2016, respiratory physicians from France, Germany, Italy, Spain, and the UK
participated in an online questionnaire designed to collect information on IPF treatment patterns in patients under
their care. Patients were categorized as treated (received approved antifibrotics) or untreated (did not receive approved
antifibrotics, but may have received other unapproved therapies). Classification of IPF diagnosis (confirmed/suspected)
and severity (‘mild’/‘moderate’/‘severe’) for each patient was based on the individual physician’s report. Patients’
perspectives were not recorded in this study.
Results: In total, 290 physicians responded to the questionnaire. Overall, 54% of patients with IPF did not receive
treatment with an approved antifibrotic. More patients had a confirmed IPF diagnosis in the treated (84%) versus
the untreated (51%) population. Of patients with a confirmed diagnosis, 40% did not receive treatment. The treated
population was younger than the untreated population (67 vs 70 years, respectively; p≤ 0.01), with more frequent
multidisciplinary team evaluation (83% vs 57%, respectively; p≤ 0.01). A higher proportion of untreated patients had
forced vital capacity > 80% at diagnosis versus treated patients. Of patients with ‘mild’ IPF, 71% did not receive an
approved antifibrotic versus 41% and 60% of patients with ‘moderate’ and ‘severe’ IPF, respectively.
Conclusions: Despite the availability of antifibrotic therapies, many European patients with confirmed IPF do not
receive approved antifibrotic treatment. Importantly, there appears to be a reluctance to treat patients with ‘mild’
or ‘stable’ disease, and instead adopt a ‘watch and wait’ approach. More education is required to address diagnostic
uncertainty, poor understanding of IPF and its treatments, and issues of treatment access. There is a need to increase
physician awareness of the benefits associated with antifibrotic treatment across the spectrum of IPF severity.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, debili-
tating, irreversible, and progressive lung disease charac-
terized by exertional dyspnea and cough [1, 2]. Patients
with IPF have a poor prognosis, with median survival
following diagnosis previously reported as lower than
that for many common types of cancer at between 2 and
5 years [1–8].
The reported incidence of IPF has been estimated to
range from 2.8 to 9.3 cases per 100,000 population per
year, in Europe and North America [9]. The prevalence
of IPF in Europe is thought to range from 1.25 to 23.4
cases per 100,000 population [10]. There is evidence that
the incidence, prevalence, and number of deaths from
IPF may be increasing [9, 11–13].
Two antifibrotic drugs, pirfenidone and nintedanib,
are approved by the European Medicines Agency and
the US Food and Drug Administration for the treatment
of IPF, and both are recommended in international treat-
ment guidelines [14]. In the Phase III ASCEND and
CAPACITY trials, pirfenidone significantly reduced the
risk of disease progression or death compared with pla-
cebo [15, 16]. In the Phase III INPULSIS trials, ninteda-
nib reduced the risk of disease progression versus
placebo in patients with IPF [17].
Following the approval and recommendation of pirfe-
nidone and nintedanib for the treatment of IPF, we con-
ducted a patient chart audit using an online physician
survey to investigate pharmacological treatment pat-
terns, understand antifibrotic prescribing, and identify
unmet needs in IPF treatment practice in Europe.
Methods
Study design and patients
This was a patient chart audit survey involving respi-
ratory physicians from France, Germany, Italy, Spain,
and the UK. Between February and March 2016, physi-
cians participated in an online questionnaire (35–40 min)
designed to collect information on IPF treatment patterns.
The questionnaire was developed by Elma Research,
an independent market research agency, on behalf of
F. Hoffmann-La Roche Ltd. The questionnaire was
available in English, French, German, Italian, and
Spanish; all responses were precoded as numbers so
translation was not required. Patients’ perspectives
were not recorded in this study.
Responses were collected from physicians who had
consulted with at least six (France, Italy, Spain) or 10
(Germany, UK) patients with IPF within the previous
3 months. The number of patients with IPF required for
each physician varied by country to account for inter-
country differences in patient population size. Italian
and British physicians were selected from a list of pane-
lists held by Elma Research, which includes physicians
willing to take part in market research. In France,
Germany, and Spain, external suppliers invited the phy-
sicians to participate on behalf of Elma Research. Physi-
cians were asked to report on the last six patients (eight
in the UK) with IPF they saw, regardless of any specific
diagnostic or therapeutic features. No patient-identifiable
data were collected and patients remained anonymous.
All respondents received a cash incentive, which was
awarded for participation in the research; i.e., this was not
on a per-patient basis. Respondents agreed to complete
the form personally, i.e., not to delegate the form comple-
tion to another staff member.
Patients were categorized as being in one of the fol-
lowing populations based on their last consultation:
 Treated population―those patients who had received
approved antifibrotics for the treatment of IPF
 Untreated population―those patients who had not
received approved antifibrotics.
In both the treated and untreated populations, patients
may have been receiving concomitant therapies, such as
N-acetylcysteine (NAC), steroids (prednisolone), im-
munosuppressants, and/or oxygen. Patients may also
have received pharmacological therapies for the palli-
ation of symptoms associated with IPF, and therapies for
concomitant conditions. The retrospective nature of the
survey meant that participation did not prompt any
change in patient care; concomitant therapies may have
been continuing or newly initiated at the last visit at the
discretion of the treating physician. It is possible that
continuing therapies may have been established in ac-
cordance with superseded clinical guidelines [2, 18].
Assessments
The questionnaire assessed a number of factors, including
baseline demographics, IPF diagnosis, disease severity,
treatments, and comorbidities (Additional files 1 and 2).
Pulmonary function and exercise capacity (6-min walk
distance [6MWD]) were recorded from diagnosis and
from the most recent consultation, where these data were
available. Classification of IPF diagnosis (confirmed/sus-
pected), severity (‘mild’/‘moderate’/‘severe’), and evolution
of severity (improvement/stable/worsening) for each
patient was based on the individual physician’s report,
i.e., no pre-defined forced vital capacity (FVC) or car-
bon monoxide diffusing capacity (DLco) threshold was
given to determine disease severity, and individual phy-
sicians may have applied different thresholds. Physicians
were asked to report the number of acute exacerbations of
IPF that resulted in hospitalization or an emergency room
visit within the last year; acute exacerbations were defined
according to clinical presentation and no standard criteria
or adjudication were applied.
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Statistical analysis
Statistical analyses were performed by a senior data analyst
from Elma Research in April 2016 using Quantum v 5.8,
once all questionnaires were completed and information
on the number and percentage of respondents per an-
swer were summarized. Comparisons between treated
and untreated populations were performed using t-tests.
In the UK and Italy, expert centers were classified as
those authorized to prescribe pirfenidone, while in France,
Germany, and Spain, expert centers were defined as:
 General university hospital with > 60 patients in care
and multidisciplinary team (MDT) available
 OR, office-based physicians who have an MDT
available and care for > 60 patients
 OR, working in a lung clinic and have an MDT.
Centers not meeting these criteria, or who were not
authorized to prescribe pirfenidone in the UK and Italy,
were classed as non-expert centers. A subgroup analysis
comparing expert and non-expert centers was performed
for the following endpoints: IPF diagnosis, time until
next consultation, goals with current treatment, and fre-
quency of acute exacerbations. Comparisons between
expert and non-expert subgroups were performed using
t-tests.
Data for the number of physicians based at centers in
the UK authorized to prescribe pirfenidone were
weighted equally for prescribing and non-prescribing
centers (50% each). In Italy, data were weighted 67% and
33% for prescribing and non-prescribing centers. To
avoid duplication of data from patients treated with pir-
fenidone in Italy or in the UK, patients reported by non-
prescribing centers as co-managed with an authorized
prescribing center within the last 3 months were not
included in the analysis.
Results
Physicians
Overall, there were 290 respondent physicians from
Germany, France, Italy, the UK, and Spain reporting on
1838 patients. Out of 119 physicians from the UK and
Italy, 80 (67.2%) were working in expert centers, which
by definition were authorized to prescribe pirfenidone
(Table 1). In France, Germany, and Spain, a total of
90/171 (52.6%) physicians were designated as being
from expert centers. MDT evaluation, which alone did
not confer status as an expert center, was available in the
centers of 213 (73.4%) physicians (Table 1).
Patients
Of the 1838 patients, 55 patients in Italy and the UK
were co-managed with a prescribing center and were
therefore excluded from further analysis to avoid
double-counting. Of the remaining 1783 patients ana-
lyzed, 955 (53.6%) did not receive treatment with either
approved antifibrotic drug (Fig. 1). The proportions of
patients starting a new medication, switching to a differ-
ent medication, or discontinuing a medication at their
last consultation were 18.5, 6.8, and 1.2%, respectively.
Excluding patients who received palliative care only or
palliative care only + oxygen therapy (N = 46), 828
patients (47.7%) received antifibrotic treatment and 909
patients (52.3%) did not receive antifibrotic treatment.
More patients in the treated population had a confirmed
diagnosis of IPF versus patients in the untreated popu-
lation (Fig. 2a). Of 1158 patients with a confirmed IPF
diagnosis, 462 (39.9%) did not receive treatment with an
approved antifibrotic drug. More patients at expert cen-
ters had a confirmed diagnosis of IPF than at non-expert
centers (70.1% vs 62.4%, respectively) (Fig. 2b); of pa-
tients with a confirmed diagnosis of IPF, antifibrotic
Table 1 Physician characteristics






United Kingdom (UK) 49 (16.9)
Spain 60 (20.7)
Type of practice
General hospital 157 (54.1)
Centre specializing in lung diseases 120 (41.4)
Office-based practice 42 (14.5)
MDT available 213 (73.4)
MDT team members
Respiratory specialist/pulmonologist 212 (99.5)
Radiologist 206 (96.7)
Pathologist 165 (77.5)
ILD/IPF Specialist Nurse 70 (32.9)
Other 44 (20.7)
Expert center (France, Germany, and Spain)a 90/171 (52.6)
General University Hospital with >60 patients
and MDTb
40 (23.4)
Office-based physicians with >60 patients
and MDT
5 (2.9)
Lung clinic with MDT availableb 47 (27.5)
Expert center (UK and Italy)a
Authorized to prescribe pirfenidone 80/119 (67.2)
For individual questions asked, please refer to Additional files 1 and 2
MDT multidisciplinary team, ILD interstitial lung disease, IPF, idiopathic
pulmonary fibrosis
aUnweighted data
bTwo centers qualified under both criteria
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treatment was received by 67.9% (461/679) of those at
expert centers compared with 49.1% (235/479) of those
at non-expert centers (Fig. 2b).
The treated population was younger than the un-
treated population and had more frequent MDT evalu-
ation. Treated patients generally had a lower proportion
of lung and cardiovascular comorbidities compared with
untreated patients (Table 2). Significantly more treated
patients were candidates for lung transplantation com-
pared with untreated patients (Table 2).
A total of 1435 patients had data available regarding
non-antifibrotic therapies that were being prescribed for
IPF at the time of questionnaire completion (this infor-
mation was not collected in France). Of 638 treated pa-
tients, the following patients also received another
therapy: NAC = 88 (13.8%), steroids = 60 (9.4%), immu-
nosuppressants = 11 (1.7%), palliative care = 3 (0.5%),
oxygen = 172 (27.0%), and other pharmacological ther-
apy = 164 (25.7%). In the untreated population (n = 797),
the following patients received: NAC = 219 (27.5%), ste-
roids = 251 (31.5%), immunosuppressants = 62 (7.8%),
palliative care = 101 (12.7%), oxygen = 300 (37.6%), and
other pharmacological therapy = 269 (33.8%).
Among untreated patients (including patients in
France), 405 patients (45%) were reported as receiving
‘no drug treatment’. Some of these patients were also
reported as receiving oxygen therapy (61 [15.1%]), other
therapy (pharmacological or non-pharmacological; 37
[9.1%]), or palliative care including morphine (13
[3.2%]). Untreated patients receiving palliative care only
were older (mean age = 81 years) than those receiving no
pharmacological treatment (71 years), oxygen therapy
(74 years), or other therapy (73 years). The most
common reasons given for why the patient was not
receiving any drug treatment were: lack of, or few,
symptoms related to IPF (27%), stable disease (26%),
old age (20%), and physician-reported good quality of
life (20%).
The three most common treatment goals reported by
physicians in both the treated and untreated populations
were to prolong survival/reduce risk of mortality, im-
prove quality of life, and stabilize disease (Table 3). To
prolong survival/reduce risk of mortality was the most
important treatment goal across all groups in the expert
versus non-expert analyses, with the exception of the
untreated non-expert population, where improvement in
quality of life was the most important treatment goal
(Table 3).
A larger proportion of the treated population (84.9%)
had ≤ 3 months until their next consultation versus the
untreated population (59.3%) (Additional file 3).
Disease severity and pulmonary function
Of 519 patients with ‘mild’ IPF, 71% (n = 370) did not re-
ceive treatment with an approved antifibrotic compared
with 41% (n/N = 361/889) and 60% (n/N = 224/375) of
patients with ‘moderate’ and ‘severe’ IPF, respectively
(Fig. 3). The proportion of patients with ‘mild’ IPF who
did not receive treatment with an approved antifibrotic
was 40.4, 41.4, 37.5, 51.4, and 44.7% in Germany, France,
Italy, the UK, and Spain, respectively.
In addition, a higher proportion of untreated versus
treated patients had FVC > 80% or did not have their















































Fig. 1 Proportion of patients that are treated or untreated across European countries. Unweighted data. For individual questions asked, please
refer to Additional files 1 and 2
Maher et al. BMC Pulmonary Medicine  (2017) 17:124 Page 4 of 12
the most recent consultation, significantly more un-
treated patients versus treated patients had ‘mild’ (40.7%
vs 18.0%; p ≤ 0.01) and/or stable (50.9% vs 31.3%; p ≤
0.01) IPF (Table 4). Likewise, more untreated patients
had FVC > 80% at last check-up than treated patients;
however, fewer untreated patients had an FVC measure-
ment at their most recent check-up compared with
treated patients (Table 4).
According to physician responses, a high proportion
of patients had experienced an acute exacerbation of
IPF in the year before completion of the survey,
resulting in hospitalization or an emergency room
visit (treated = 47.5% vs untreated = 39.6%) (Fig. 4a). A
total of 16% of patients with ‘mild’ IPF had a
physician-reported acute exacerbation compared with
38% and 32% of patients with ‘moderate’ and ‘severe’ IPF,
respectively. Patients at non-expert centers had slightly
more acute exacerbations than patients at expert centers,
whether they were treated or untreated (Fig. 4b).
Discussion
Our results show that approximately 40% of European
patients with confirmed IPF do not receive antifibrotic
treatment despite the regulatory approval of two antifi-
brotic therapies and the recommendation in inter-
national guidelines that the majority of individuals with
IPF should be offered antifibrotic treatment. Indeed, at
the time of the survey, antifibrotic therapy had been
available for at least 2 years in all the countries surveyed,
and it is therefore important to consider reasons for the
observed treatment pattern.
Treatment requires a confident diagnosis of IPF, and it
may be that a lack of awareness about IPF as a potential




























































































Fig. 2 Type of diagnosis, (a) pooled population (b) expert versus non-expert centers*p≤ 0.01 for (a) treated population versus untreated population
and (b) expert population versus non-expert population. Excluding patients receiving only palliative care. Number of patients with a confirmed
diagnosis at expert (691/993, 69.6%) versus non-expert centers (494/790, 62.5%)―p≤ 0.01. Number of patients with confirmed IPF treated at expert
(461/679, 67.9%) versus non-expert centers (235/479, 49.2%)―p ≤ 0.01. For individual questions asked, please refer to Additional files 1 and 2.
IPF idiopathic pulmonary fibrosis
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for MDT diagnostic assessment have an impact upon
treatment practices. Our results show that a higher pro-
portion of untreated patients had suspected IPF than
treated patients and a lower proportion of untreated pa-
tients had an MDT evaluation at diagnosis. Uncertain
diagnosis is also a key barrier to treatment in patients
with suspected IPF, which will potentially be addressed
by two clinical trials currently investigating the efficacy
of antifibrotics in non-IPF interstitial lung diseases
(NCT03099187 and NCT02999178).
In our analysis of treatment patterns in expert versus
non-expert centers, more patients had a confirmed diag-
nosis of IPF at expert centers. In addition, a higher pro-
portion of patients in the untreated population did not
have an FVC (12% vs 8%), DLco (23% vs 15%), or
6MWD (57% vs 36%) measurement at baseline com-
pared with the treated population. These differences
between the untreated and treated populations could re-
flect a number of issues, including difficulty with in-
terpreting dynamic changes in pulmonary function or
reduced monitoring in patients considered to be unsuit-
able for treatment by their physician.
Previous studies have shown that patients often visit
several healthcare professionals before being diagnosed
with IPF, with the process of obtaining a confirmed diag-
nosis taking in excess of 1 year in the majority of cases
[19, 20]. Misdiagnosis and a lack of knowledge about
IPF in primary care are cited as key reasons for delayed
referral to specialist centers [20, 21]. Our data suggest
that referral to a non-specialist pulmonologist may be
another barrier to diagnosis and treatment access. Pa-
tients in several areas across the EU have reported lim-
ited access to a full MDT to facilitate diagnosis [21].
Once a diagnosis has been made, areas of unmet needs
Table 2 Patient characteristics
Factor, mean (SD) or n (%) Treated (N = 828) Untreated (N = 909)
Mean (SD) age, years 66.6 (9.3) 70.1 (11.4)**
Male 568 (68.6) 570 (62.7)**
MDT evaluation 687 (83.0) 520 (57.2)**
Confirmed IPF 696 (84.1) 462 (50.8)**
IPF severity at diagnosis
Mild 213 (25.7) 395 (43.5)**
Moderate 530 (64.0) 367 (40.4)**
Severe 85 (10.3) 147 (16.2)**
Mean (SD) time from diagnosis to most recent consultation, months 15.8 (21.8) 15.9 (22.4)
Symptomatic at initiation of current treatment 746 (90.1) 430 (85.4)a**
Candidate for lung transplantation 154 (18.6) 66 (7.3)**
Lung comorbidities 323 (39.0) 460 (50.6)**
Emphysema 187 (22.6) 299 (32.9)**
Lung cancer 20 (2.4) 46 (5.1)**
Pulmonary hypertension 184 (22.2) 229 (25.2)
CV comorbidities 320 (38.6) 406 (44.7)*
High risk of coronary artery disease 131 (15.8) 153 (16.8)
Coronary artery disease without history of MI or stroke 119 (14.4) 143 (15.7)
Coronary artery disease with history of MI 88 (10.6) 135 (14.9)**
Other comorbidities
GERD 262 (31.6) 257 (28.3)
Depression 199 (24.0) 200 (22.0)
Obstructive sleep apnea syndrome 103 (12.4) 109 (12.0)
Increased risk of bleedingb 38 (4.6) 44 (4.8)
Other 111 (13.4) 149 (16.4)
p values represent treated population versus untreated population. *p ≤ 0.05; **p ≤ 0.01
aN = 504, patients who received no treatment were excluded
be.g., due to use of anticoagulation therapy or concomitant diseases
For individual questions asked, please refer to Additional file 2
CV cardiovascular, GERD gastroesophageal reflux disease, IPF idiopathic pulmonary fibrosis, MDT multidisciplinary team, MI myocardial infarction, SD
standard deviation
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include a lack of awareness of available approved antifi-
brotic therapy and/or information and resources on
pulmonary fibrosis from both a patient and a healthcare
professional perspective [22–24]. Indeed, in our experi-
ence, informed patients with a good knowledge of their
condition and the available treatments are more likely
to request referral to specialist care and/or access to
treatment than those with less knowledge about their
condition. Similar factors were highlighted in the
European IPF Patient Charter [21] and may contribute
to the delayed diagnosis and treatment of IPF.
Our results indicate that many patients with IPF that
is perceived to be ‘mild’ or ‘stable’ by their physician
were not treated with an antifibrotic, suggesting physi-
cians were adopting a ‘watch and wait’ approach. Indeed, a
large group of patients who did not receive an antifibrotic
received no treatment at all, with the most common rea-
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Fig. 3 Overall proportion of treated and untreated patients based on current disease severityClassification of disease severity was based on the
subjective determination of individual physicians for each patient. For individual questions asked, please refer to Additional files 1 and 2.
IPF idiopathic pulmonary fibrosis
Table 3 Most important treatment goals with current treatment













Prolong survival/reduce risk of mortality 402 (48.6) 174 (43.0) 273 (49.5) 129 (46.6) 80 (45.5) 94 (41.0)
Improvement of quality of life 314 (37.9) 179 (44.2)* 194 (35.2) 120 (43.3) 75 (42.6) 104 (45.4)
Overall disease stabilization 334 (40.3) 152 (37.5) 234 (42.5) 100 (36.1) 64 (36.4) 88 (38.4)
Stabilization of predicted% FVC 279 (33.7) 56 (13.8)** 176 (32.0) 102 (36.8) 23 (13.1) 33 (14.4)
Stabilization of quality of life 248 (30.0) 135 (33.3) 164 (29.8) 83 (30.0) 70 (39.8) 65 (28.4)
Improvement of symptoms 236 (28.5) 142 (35.1)* 161 (29.2) 76 (27.4) 57 (32.4) 85 (37.1)
Stabilization of symptoms 215 (26.0) 143 (35.3)** 135 (24.5) 81 (29.2) 68 (38.6) 75 (32.8)
Decrease in number of exacerbations 208 (25.1) 94 (23.2) 153 (27.8) 55 (19.9) 40 (22.7) 53 (23.1)
Avoid pulmonary hospitalizations 156 (18.8) 122 (30.1)** 101 (18.3) 55 (19.9) 46 (26.1) 76 (33.2)
Stabilization of predicted% DLco 92 (11.1) 19 (4.7)** 61 (11.1) 31 (11.2) 3 (1.7) 15 (6.6)
DLco carbon monoxide diffusing capacity; FVC forced vital capacity
Respondents were asked to pick the three most important goals; for individual questions asked, please refer to Additional file 2
p values represent treated population versus untreated population. *p ≤ 0.05; **p ≤ 0.01
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disease progression. The data gathered in this survey sug-
gest that treated patients had more severe disease than
untreated patients: they were more likely to have an FVC
< 70% at diagnosis and follow-up, they were more likely to
have disease rated as ‘moderate’ by their physician, they
tended to have more acute exacerbations than untreated
patients, and they were more likely to be candidates for
lung transplantation (although it should be acknowledged
that this may have been because they were younger and/
or had fewer comorbidities than untreated patients, rather
than reflecting more severe disease).
One possible explanation for patients with ‘mild’ or
‘stable’ IPF remaining untreated is a lack of physician
confidence in the evidence base. The limitations of our
survey design prevented further investigation of this pos-
sibility; however, a survey of respiratory physicians has
previously reported that physicians who waited for dis-
ease progression before initiating antifibrotic therapy
were less likely to agree that antifibrotics can signi-
ficantly slow disease progression compared with physi-
cians who treated within 4 months of diagnosis [25].
However, the available evidence increasingly points to-
ward early intervention in this progressive, unpredic-
table, irreversible, and fatal disease [1, 26–31], especially
as experience from other lung diseases suggests that
physicians tend to underestimate the severity of disease
[32, 33]. Antifibrotic treatment in patients with limited
lung function impairment has been demonstrated to re-
duce FVC decline compared with placebo [28, 30, 31],
and patients who progress on antifibrotic therapy still
appear to benefit from continued therapy [34]. Further-
more, in a post-hoc analysis of data from the pooled
ASCEND and CAPACITY population, pirfenidone
showed similar efficacy in patients with more-preserved
and less-preserved baseline lung function [27], a finding
that has also been reported with nintedanib in a post-hoc
subgroup analysis of data from the INPULSIS trials [29].
These data suggest that earlier treatment with antifibrotics
may help to preserve lung function at higher levels if
started in the early stages of the disease.
Goals for patient care may also have influenced treat-
ment decisions. Overall, the three most important goals
given by physicians were to prolong survival or reduce
the risk of mortality, improve quality of life, and stabilize
disease. However, the importance placed on these goals
differed in treated and untreated patients, with improve-
ment and/or stabilization in quality of life being more
frequent for untreated patients (78%) than treated
patients (68%). There may be a perception among physi-
cians that antifibrotic treatment might have a detri-
mental effect on quality of life, possibly via the common
side effects associated with treatment, and that the po-
tential risks outweigh the benefit of treatment, particu-
larly in patients with preserved lung function. Validating
IPF-specific quality-of-life endpoints is still a work in
progress and, so far, findings have been inconsistent with
the treatment response (as measured with clinical end-
points) [35]. However, the available evidence from clin-
ical trials suggests antifibrotic treatment results in
Table 4 Disease characteristics
Factor, n (%) Treated N = 828 Untreated N = 909
Diagnostic values
FVC
FVC > 80% 94 (11.4) 163 (17.9)**
FVC 71–80% 143 (17.3) 183 (20.1)
FVC 50–70% 425 (51.3) 335 (36.9)**
FVC < 50% 102 (12.3) 122 (13.4)
FVC not tested 64 (7.7) 106 (11.7)**
DLco
DLco < 35% 74 (8.9) 85 (9.4)
DLco ≥ 35% 634 (76.6) 612 (67.3)**
DLco not tested 121 (14.6) 212 (23.3)**
6MWD
6MWD < 150 m 71 (8.6) 71 (7.8)
6MWD ≥ 150 m 460 (55.6) 323 (35.5)**
Not tested 297 (35.9) 516 (56.8)**
Last visit
Mild IPF (current level) 149 (18.0) 370 (40.7)**
FVC
FVC > 80% 39 (4.7) 119 (13.1)**
FVC 71–80% 116 (14.0) 134 (14.7)
FVC 50–70% 427 (51.6) 279 (30.7)**
FVC < 50% 148 (17.9) 141 (15.5)
FVC not tested 98 (11.8) 236 (26.0)**
Evolution in severity levela from diagnosis to last check-up
Improvement 38 (4.6) 36 (4.0)
Stable 637 (76.9) 782 (86.0)**
Worsening 154 (18.6) 92 (10.1)**
Type of progression
Stable IPF 259 (31.3) 463 (50.9)**
Slow progressing 383 (46.3) 291 (32.0)**
Progressive 159 (19.2) 114 (12.5)**
Fast progressing 27 (3.3) 41 (4.5)
For individual questions asked, please refer to Additional file 2
6MWD 6-min walk distance, DLco carbon monoxide diffusing capacity,
FVC forced vital capacity, IPF idiopathic pulmonary fibrosis
aEvolution in severity levels was defined as follows: Improvement = from
Moderate to Mild/from Severe to Moderate or Mild; Stable = unchanged level
of severity at diagnosis to last check-up; Worsening = from Mild to Moderate
or Severe/from Moderate to Severe
p values represent treated population versus untreated population.
*p ≤ 0.05; **p ≤ 0.01
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statistically non-significant improvements in quality-of-
life endpoints or has no net effect on these endpoints
[15, 17, 36].
Access to IPF treatment differs in each country, for ex-
ample because of reimbursement restrictions, and this
may also have resulted in some differences in treatment
practices. In Italy, patients must have a DLco > 35% and
be < 80 years of age to be eligible for treatment re-
imbursement, while patients in the UK and in sev-
eral regions in Spain must have an FVC < 80%.
Interpretation of our data is limited because the sur-
vey did not specifically ask about access restrictions;
however, the proportion of patients in the UK with
‘mild’ disease who were untreated was higher (51.4%)
compared with countries without an upper FVC limit,
such as France and Germany (41.1 and 40.4%, respect-
ively). Overall, a greater proportion of the untreated popu-
lation had an FVC > 80% compared with treated patients,
both at diagnosis (17.9% vs 11.4%) and at last check up
(13.1% vs 4.7%).
Both pirfenidone and nintedanib are associated with a
number of adverse events, which may limit tolerability
or result in treatment discontinuation due to potentially
harmful events, e.g., rare elevations in liver enzymes
[37, 38]. Patients may occasionally be prevented from
taking specific antifibrotics due to contraindications
[37, 38]. Although emphysema and lung cancer are not
direct contraindications to antifibrotic treatment, un-
treated patients in our analysis were more likely to have
these comorbidities. The results suggest that physicians
are reluctant to treat patients with other lung diseases,
perhaps due to a perception that these individuals may
be more susceptible to adverse effects from treatment,
or concerns about the benefit of treating fibrosis in
individuals who may have other life-limiting disease.
It should be noted, however, that patients with some
degree of emphysema were included in the CAPACITY
and INPULSIS trials [15, 17].
In Europe, pirfenidone is indicated for the treatment
of ‘mild to moderate’ IPF [37], thereby excluding
detaertnUdetaerT
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patients with ‘severe’ disease, often considered to be
those with FVC < 50%. In fact, a minority of treated
patients in our analysis had an FVC < 50%, and this
proportion was similar in the untreated population.
Other reasons for non-treatment could include patient
choice, particularly in those with ‘mild disease’, or lack of
adherence to treatment due to social or personal
circumstances.
The focus of the current analysis was to investigate
antifibrotic treatment patterns; however, in general,
many patients in our analysis appeared to receive in-
adequate additional symptom management measures.
Treatment guidelines recommend oxygen supplemen-
tation and other therapies for symptom control and
management of comorbidities [2]; however, oxygen
therapy and supportive treatments, such as anti-cough
treatments, vaccines, etc., were used in only half of pa-
tients overall and in approximately a quarter of patients
in the treated population. Supportive treatments for co-
morbidities, symptom control, or side-effect manage-
ment may help with adherence to antifibrotic therapy
and also improve patients’ perceptions of treatment.
Furthermore, only 59/1783 patients (3%) overall re-
ceived palliative care (46 patients were reported as hav-
ing received palliative care only ± oxygen and a further
13 were reported as receiving no drug treatment and
palliative care only ± oxygen). Amongst patients with
IPF considered ‘severe’ by their doctor, only 10% were
receiving palliative care. This is similar to previous
findings, which highlighted poor or variable access
and ineffective utilization of palliative care services,
despite increasing evidence that access to palliative
care services or having end-of-life discussions early in
the course of IPF is desired by patients and can also
improve quality of life, symptom control, and mood
[21, 39–41]. Variable information regarding the disease
and treatment, and access to other aspects of IPF manage-
ment, such as supplementary oxygen, comorbidities, and
palliative care, have been identified as unmet needs in the
IPF Patient Charter; our observations support the findings
of the Charter and suggest improvements in IPF aware-
ness are still needed [21].
The conclusions from this study are limited by the na-
ture of questionnaire-based research, which may have
introduced bias. Furthermore, the quality of the data col-
lected in this survey was reliant upon case notes re-
corded by physicians during patient consultations prior
to their awareness of the survey. Physicians might not
have reported on consecutive patients as directed, and
may instead have selected cases that they considered
representative of their medical decision making. The
number of acute exacerbations resulting in hospitalization
or an emergency room visit in the previous year (40–47%)
was much higher than expected when compared with an
annual acute exacerbation rate of 5–10% in the published
literature [42–44], suggesting that these data are limited
by the subjective acute exacerbation diagnoses made by
individual physicians and the lack of specific criteria defin-
ing acute exacerbations in the survey. There is also no
consensus on how to categorize disease severity or disease
progression in IPF, and our analysis is limited by the sub-
jective determination made by individual physicians as to
whether disease was ‘mild’, ‘moderate’, or ‘severe’, or
whether the patient had stable or worsening disease. We
recognize that there is an unmet need for an objective
severity staging system to capture the nature and progres-
sion of IPF. In particular, ‘mild’ is an inadequate descrip-
tion of a disease that can impair quality of life and
undergo periods of acute exacerbation even in its early
stages, and other classifications including ‘subclinical IPF’
may become more appropriate in the future. Finally, this
analysis focused on five European countries (France,
Germany, Italy, Spain, and the UK); therefore, the results
may not be comparable in the rest of the world.
Treatment patterns in IPF will require further eva-
luation in future studies as more evidence is presented
regarding available pharmacological treatments. The im-
pact of early intervention and the potential for combin-
ing antifibrotics need further investigation [45, 46].
Conclusion
In summary, this study highlights the high proportion of
patients who are diagnosed with IPF, but do not receive
antifibrotic treatment. The factors affecting treatment pre-
scription in this analysis appear to involve diagnostic un-
certainty and a lack of understanding around important
features of both the disease and treatment as well as issues
relating to treatment access. We acknowledge that a small
proportion of patients will make an informed decision to
not proceed with treatment. However, the adoption by
physicians of a ‘watch and wait’ approach is of particular
concern when evidence suggests immediate intervention
can improve outcomes for patients with IPF. Increased
education about IPF, in line with the European IPF Patient
Charter, may help to empower patients to become more
actively involved in treatment decisions and may improve
treatment patterns in patients with IPF.
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